MK-8189
MK-8189 is a selective phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma Royalty may refer to: * Any individual monarch, such as a king, queen, emperor, empress, etc. * Royal family, the immediate family of a king or queen regnant, and sometimes his or her extended family * Royalty payment for use of such things as in .... See also * Balipodect * Mardepodect References {{reflist PDE10 inhibitors Pyridines Pyrimidines Cyclopropanes Thiadiazoles Secondary amines Drugs developed by Merck ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]